the core of our corporate values
Zylox-Tonbridge: Neurovascular Embolization Coils obtains NMPA approval for marketing in advance, demonstrating the strong R&D capabilities
On September 27th, Zylox-Tonbridge (2190.HK), one of the leading players in neuro- and peripheral- interventional medical device market in China, announced that the neurovascular embolization coils independently developed by its subsidiary Zhuhai Tonbridge Medical Technology Co., Ltd. (hereinafter referred to as "Tonbridge Medical") has obtained the marketing approval by the National Medical Products Administration of People’s Republic of China (the “NMPA”) ahead of the expected 2021 Q4 as disclosed in its interim performance report, which marks that Tonbridge Medical has entered an all-new stage in the interventional treatment of Intracranial Hemorrhagic Stroke.
Our coil system is a mechanical detachable coil which is competitive in softness, mechanical detachment and wide-ranging specifications. The pre-marketing clinical trial results demonstrated our coil system is equal to the latest products of international brands in the safety and effectiveness of the treatment for the patients experiencing irregular aneurysms and ruptured aneurysms.
As the aging accelerates and domestic neuro-interventional technology rapidly evolves, China's market of neuro-interventional medical devices is booming. The Report on Stroke Prevention and Treatment in China (2020) reported a 7% detection rate of intracranial aneurysms in China, which is still rising. According to Frost & Sullivan analysis, the volume of intracranial aneurysm interventional procedures in China has increased from 52,000 in 2018 to 73,700 in 2021, and will be up to 444,000 in 2030, marking a huge market potential.
As Zylox-Tonbridge’s Neuro-intervention Business Division, Tonbridge Medical is committed to providing Chinese stroke patients with full solutions covering both ischemic and hemorrhagic stroke. Currently, it owns 21 products approved and under development, seven of which had obtained NMPA approvals as of September 2021. For ischemic stroke, Tonbridge ThrombiteTM Clot Retriever Device, Tonbridge GyclineTM Intracranial Support Catheter and Tonbridge DayuTM Balloon Guiding Catheter (BGC) have been commercialized. In the hemorrhagic stroke field, Tonbridge GekkoTM Coil System is ready to be commercialized, and the Tonbridge KylinTM flow diverter is in clinical stage.
Since August, our microcatheter and coil system both developed in-house have been approved by NMPA ahead of the expected time, showcasing Zylox-Tonbridge’s strong R&D capabilities. Zylox-Tonbridge commits itself to providing patients with premium and affordable innovative medical devices and solutions, so that everyone has access to the high-quality life brought by advanced medical technology.